Primary-source record
Decision-gradeTopline results
Pfizer tilrekimig Phase 2 meets EASI-75 primary endpoint in atopic dermatitis
The Phase 2 trial of tilrekimig met the primary endpoint of statistically significant EASI-75 improvement versus placebo at Week 16 across all doses in adults with moderate-to-severe atopic dermatitis. Key secondary vIGA 0/1 and itch reduction endpoints were also positive with a favorable tolerability profile. This supports the already-initiated Phase 3 program in atopic dermatitis, asthma, and COPD.
Key facts
- Filed
- Oct 1, 2026, 06:30 AM
- Event
- Topline results
- Direction
- Positive
- Company
PFEPfizer- Asset
- tilrekimig
- Source
- Company press release
- Confidence
- Sourced
- EASI-75 Stage 1
- 62.5% vs 19.9% (p=0.0008)
- EASI-75 Stage 2
- 58.5%, 61.0%, 47.8% vs 9.1% (all p<0.003)
- vIGA 0/1 Stage 1
- 30.3% vs 11.8% (p=0.0251)
- vIGA 0/1 Stage 2
- 26-27% vs 0% (all p<0.006)
Source excerpt
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study Study met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific antibody Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. The findings were shared today in an oral presentation at the 35th European Academy of Dermatology and Venereology (EADV) Annual Congress in Vienna, Austria. Tilrekimig is an investigational, potential first-in-class trispecific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation through concurrent high-affinity binding to interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP). By directly blocking TSLP together with its downstream effectors, tilrekimig is designed to provide broader cytokine pathway coverag